BPC-157 is sold more for healing than for anything else: tendons, ligaments, joints, gut. The reputation is built on a large animal literature, and the honest summary is about who produced it and in which species. This page counts that literature, grades it by design, and lays out every human result found, with what each one measured.
What has been reported as side effects is on our BPC-157 side effects page, and the figures sources quote are on our BPC-157 dosage page. A plain explainer of the molecule is Peptide Lexicon's BPC-157 entry. Nothing here is a recommendation; an injury belongs with a clinician.
The literature, counted
A PubMed search on 15 October 2026 for "BPC 157", "BPC-157" or "pentadecapeptide BPC" returned 231 records. Three counts describe them:
| Count | Records | Share |
|---|---|---|
| All records | 231 | 100% |
| Listing Predrag Sikiric (University of Zagreb) as an author | 175 | 76% |
| Indexed as reviews | 50 | 22% |
| Indexed as a clinical trial or randomised controlled trial | 0 | 0% |
| Mentioning tendon or ligament | 31 | 13% |
| Mentioning inflammation, inflammatory or colitis | 88 | 38% |
The 76% figure is ours, from the author filter; it is a floor, since some papers from that laboratory list only its other members as authors. It matters because a body of work that comes overwhelmingly from one laboratory has not yet been tested by the usual check of independent groups repeating it. The reviews add volume without adding data — many come from the originating laboratory.
Independent readers have reached the same picture. A 2025 systematic review in HSS Journal (PMID 40756949) screened 544 articles and kept 36 for orthopaedic sports medicine: 35 preclinical and one clinical. A 2025 scoping review from the University of Utah (PMID 40789979) found three human pilot studies in total and concluded BPC-157 "should be considered investigational."
What the rat studies report
The tendon and ligament claims trace back to a series of rat experiments, almost all from the Zagreb group:
| Injury model | Study | What was reported |
|---|---|---|
| Cut Achilles tendon | Staresinic et al., J Orthop Res 2003 (PMID 14554208) | Faster functional and structural healing; tendon cells grew faster in the dish |
| Achilles detached from bone | Krivic et al., J Orthop Res 2006 (PMID 16583442) | Better tendon-to-bone healing; offset a corticosteroid's harm |
| Cut quadriceps muscle | Staresinic et al., J Orthop Res 2006 (PMID 16609979) | Improved muscle healing |
| Knee ligament injury | Cerovecki et al., J Orthop Res 2010 (PMID 20225319) | Improved ligament healing (the compound was coded PL 14736) |
| Crushed muscle | Novinscak et al., Surg Today 2008 (PMID 18668315) | Faster recovery |
A Taiwanese group added laboratory work on tendon cells — more outgrowth and migration (PMID 21030672) and more growth-hormone receptor on tendon fibroblasts (PMID 25415472). The mechanisms proposed across the literature are new blood-vessel growth (through VEGFR2) and nitric-oxide signalling. These are plausible explanations of the animal results; none has been measured in an injured person.
The inflammation claim has the same shape. Most of the 88 inflammation-related records are rat models — chemically induced colitis, stomach lesions from drugs or alcohol, inflamed wounds — in which BPC-157 reduced visible damage and inflammatory markers. BPC-157 was first isolated as a fragment of a protein in gastric juice, which is why the gut models came first and why the oldest human study is in the bowel.
The one independent tendon replication
The most useful study in the record may be the least cited. In 2026 an Istanbul group repaired cut Achilles tendons in 32 rats and gave each group a placebo, BPC-157, TB-500 or both for four weeks (Biçer et al., Joint Diseases and Related Surgery 2026, PMID 42542926).
- Load to failure (how much force the healed tendon took before tearing) was higher with BPC-157 than control, but not statistically significant. TB-500's increase was significant.
- Total histology scores were numerically better with BPC-157 and again not significant. TB-500 was significant on both scales.
- Combining the two added nothing over either alone.
It is one small study at one dose, and a non-significant result in eight rats per group is not proof of no effect. But it is the only tendon experiment found from outside the originating laboratory, and its BPC-157 arm did not reproduce the size of effect the earlier papers describe. Our TB-500 vs thymosin beta-4 page covers what TB-500 actually is.
Every human result, and what it measured
| Report | People | Design | Outcome measured | Result |
|---|---|---|---|---|
| Ulcerative colitis, Ruenzi et al. 2005 | 53 randomised, about half on BPC-157 | Placebo-controlled, 2 weeks of enemas | Disease activity | Known only from a meeting abstract; no full paper |
| Knee pain, Lee and Padgett 2021 | 17 treated, 16 reached | Retrospective chart review, phone survey | Self-reported pain relief | 11 of 12 on BPC-157 alone reported "significant improvement"; 3 of 4 on BPC-157 plus thymosin β4 |
| Interstitial cystitis, Lee, Walker and Ayadi 2024 | 12 women | Single arm, one 10 mg injection into the bladder wall | Global Response Assessment | 10 reported complete resolution, 2 reported 80% |
| Intravenous safety, Lee and Burgess 2025 | 2 volunteers | 10 mg then 20 mg IV | Blood tests, symptoms | No changes, no side effects |
Three features run across the three published reports. All share one first author, one journal (Alternative Therapies in Health and Medicine) and private-clinic settings in Florida. None had a control group. None used an imaging or physical measure of healing — the knee study, by its own description, used "no specific tools" for function or pain.
The knee study is read in two ways in the literature. Its abstract reports 11 of 12 improved; the 2025 HSS review summarised it as 7 of 12 with relief lasting more than six months. Both can be true — they count different things — but a reader citing "91%" is citing the looser of the two, from a phone survey months after the injection.
FDA's reviewers, evaluating BPC-157 for the July 2026 compounding advisory committee, found these same five clinical reports and no study by the subcutaneous, oral or nasal routes that sellers describe; that review is read in full on our side effects page.
What is registered and has not reported
ClinicalTrials.gov, searched 15 October 2026, holds four records for BPC-157:
- NCT07437547 — hamstring strain, phase 2, 120 people with an MRI-confirmed grade II tear, randomised to BPC-157 or placebo on top of the same rehabilitation. Primary outcomes: days to return to sport and change in injury volume on MRI read blind. Recruiting; primary completion estimated February 2027. Sponsor: Hudson Biotech.
- NCT07803250 — after rotator-cuff repair surgery, 30 people, daily subcutaneous BPC-157 or saline for 90 days, fully blinded; primary outcome shoulder strength. Not yet recruiting. Sponsor: University of Arkansas.
- NCT07752381 — 40 physically active adults, a gummy supplement stated to contain 500 µg of BPC-157 per serving, eight weeks, no control group. Primary outcomes CRP, IL-6 and self-reported swelling. Completed in November 2025; no results posted.
- NCT02637284 — an oral tablet (PCO-02) in healthy volunteers, phase 1, 2015. Status unknown; no results posted.
The first two are the first placebo-controlled trials of BPC-157 for an injury to be registered. When they report, the healing question will have its first real human answer. A count of registered trials across all the compounds sold for healing is on Peptide Lexicon's peptides for healing page.
Status
- FDA: not an approved drug. In July 2026 the agency's Pharmacy Compounding Advisory Committee voted to recommend BPC-157 for the list of substances pharmacies may compound from; the vote is advisory and FDA had not acted on it. Our 503A category 2 page tracks that process.
- Sport: WADA names BPC-157 in section S0, prohibited at all times; MuscleLedger's BPC-157 page sets out the sanctions record.
- Forms: oral and arginate-salt versions are sold with their own claims; our BPC-157 vs pentadeca arginate page covers the difference.
What the record does not contain
- A controlled human trial of BPC-157 for any tendon, ligament, muscle, joint or gut injury that has reported results.
- A human measurement of an inflammatory marker after BPC-157.
- Any human study of subcutaneous injection, the route most products are sold for.
- An independent replication in animals that reproduces the originating group's effect sizes; the one found did not reach significance.
- Any study in women specifically. Population-level questions are on our peptides before and after page, which sets this compound beside the approved peptides that do have outcome trials.
Sources and dates
Read 15 October 2026: PubMed searches and counts as stated above; abstracts of PMIDs 40756949, 40789979, 42542926, 34324435, 39325560 and 40131143; PubMed records for PMIDs 14554208, 16583442, 16609979, 20225319, 18668315, 21030672 and 25415472; ClinicalTrials.gov records NCT07437547, NCT07803250, NCT07752381 and NCT02637284. The Ruenzi 2005 abstract and the FDA review are as cited on our BPC-157 side-effects page (FDA briefing document for the July 23–24, 2026 Pharmacy Compounding Advisory Committee, evaluation dated 2026-05-11).